[Form 4] BECTON DICKINSON & CO Insider Trading Activity

Rhea-AI Filing Summary

Becton Dickinson & Co executive Michael David Garrison reported multiple stock transactions. On 01/15/2026, he exercised 3,054 stock appreciation rights at an exercise price of $167.91 per share, receiving 3,054 shares of common stock. He then disposed of 2,454 shares at $209 per share and sold 600 additional shares at $209 and 1,010 shares at $206.54.

After these transactions, he directly owned 12,095 shares of Becton Dickinson common stock. The filing notes that the reported transactions were made under a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2025.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 5 txns

Insider Garrison Michael David

Role EVP & Pres Med.Essntl&BioPharm

Sold 1,610 shs ($334K)

Approx. gross sale proceeds $334K

Approx. exercise cost $513K

Type	Security	Shares	Price	Value
Exercise	Stock Appreciation Rights	3,054	$0.00	$0.00
Exercise	Common Stock	3,054	$167.91	$513K
Disposition	Common Stock	2,454	$209.00	$513K
Sale	Common Stock	600	$209.00	$125K
Sale	Common Stock	1,010	$206.54	$209K

Holdings After Transaction: Stock Appreciation Rights — 0 shares (Direct); Common Stock — 12,095 shares (Direct)

Footnotes (1)

1. F1. The stock appreciation rights vested in four annual installments beginning one year from the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/16/2026 - 03:43 PM Learn about SEC filing dates

FAQ

Who is the insider trading Becton Dickinson (BDX) shares in this Form 4?

The reporting person is Michael David Garrison, who serves as EVP & President, Medical Essential & BioPharmaceutical at Becton Dickinson & Co.

What derivative securities did the BDX executive exercise in this filing?

He exercised 3,054 Stock Appreciation Rights with an exercise price of $167.91 per right, resulting in 3,054 shares of Becton Dickinson common stock.

How many Becton Dickinson (BDX) shares did the executive sell or dispose of?

On 01/15/2026 he disposed of 2,454 shares of common stock at $209 per share and also sold 600 shares at $209 and 1,010 shares at $206.54 per share.

How many Becton Dickinson (BDX) shares does the insider own after these transactions?

Following the reported transactions, Michael David Garrison directly owns 12,095 shares of Becton Dickinson common stock.

Were the BDX insider trades made under a Rule 10b5-1 trading plan?

Yes. The filing states that the reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 13, 2025.

What does the vesting footnote say about the BDX stock appreciation rights?

The footnote explains that the stock appreciation rights vested in four annual installments, beginning one year from the grant date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Garrison Michael David

(Last) (First) (Middle)

C/O BECTON, DICKINSON AND COMPANY

1 BECTON DRIVE

(Street)

FRANKLIN LAKES NJ 07417

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BECTON DICKINSON & CO [ BDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Pres Med.Essntl&BioPharm

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/15/2026		M		3,054	A	$167.91	16,159	D
Common Stock	01/15/2026		D		2,454	D	$209	13,705	D
Common Stock	01/15/2026		S		600	D	$209	13,105	D
Common Stock	01/15/2026		S		1,010	D	$206.54	12,095	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Appreciation Rights	$167.91	01/15/2026		M			3,054	11/26/2017(1)	11/26/2026	Common Stock	3,054	$0	0	D

Explanation of Responses:

1. The stock appreciation rights vested in four annual installments beginning one year from the grant date.

Remarks:

The reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 13, 2025.

	Donna Kalazdy, by power of attorney from Michael David Garrison	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.